We found that 93 protein-coding cancer genes carried probable driver ... understanding of the origins and consequences of somatic mutations in breast cancer. Figure 3: Extraction and contributions ...

Somatic mutations have been extensively characterized in breast cancer, but the effects of these genetic alterations on the proteomic landscape remain poorly understood. Here we describe ...

Recent research and genomic studies have revealed a number of genes that accumulate somatic, or non-inherited, mutations and alterations in estrogen receptor positive (ER+) breast cancer.

Oncotarget published "Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients" which reported that the association between genetic ...

Breast cancer can run in families ... to cancer are acquired during your lifetime. These are called somatic mutations. Somatic mutations happen due to things like the natural aging process ...

BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].” Somatic HER2 mutations are a novel class ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

These are called “somatic mutations,” and some can also contribute to breast cancer development. If a loved one has been diagnosed with a type of hereditary breast cancer, it means a germline ...

A small proportion of women who receive anti-estrogen treatment after breast cancer surgery have worse outcomes. This is associated with mutations in the estrogen receptor gene, according to a ...

mutation carriers with metastatic breast cancer (MBC). In addition, PARPi have demonstrated efficacy in patients with ovarian cancer with somatic BRCA1 or BRCA2 (sBRCA1/2) mutations. Other genes also ...